Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
Navidea Biopharmaceuticals, Inc. (NAVB)
NASDAQ:AMEX Investor Relations:
ir.navidea.com
Company Research
Source: Seeking Alpha
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript Navidea Biopharmaceuticals, Inc. (NYSEMKT: NAVB Company Participants Jed Latkin - Chief Executive Officer, Chief Financial Officer and Chief Operating Officer Michael Rosol - Chief Medical Officer Erika Gibson - Director, Finance and Administration Conference Call Participants Jason McCarthy - Maxim Group Operator Greetings, and welcome to the Navidea Biopharmaceuticals’ Q2 2019 Earnings Conference Call. At this time, all participants are in a listen-only-mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jed Latkin, CEO. Please go ahead. Good afternoon and welcome, everyone, to Navidea’s Second Quarter 2019 Earnings Call. I’m Jed Latkin, Chief Executive Officer of Navidea Biopharmaceuticals. This call will cover Navidea’s financial and ope
Show less
Read more
Impact Snapshot
Event Time:
NAVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAVB alerts
High impacting Navidea Biopharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NAVB
News
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat